Seidman Cancer Center

Wednesday, April 05, 2017

UH Seidman Cancer Center’s Five Star Sensation Shines Culinary Spotlight on Cleveland

CLEVELAND — Cleveland’s most celebrated benefit--Five Star Sensation--features over 80 acclaimed chefs and vintners from around the world. Michael Symon, renowned Iron Chef and co-host of ABC’s The Chew, leads this year’s Five Star Sensation as the event’s Host Chef.
 
Five Star Sensation, Northeast Ohio’s premier food and wine event, has raised more than $18 million for University Hospitals (UH) Seidman Cancer Center since the event began in 1987. Tickets are now available for this extraordinary celebration of food and wine to be held Saturday, June 24, at Cuyahoga Community College in Highland Hills, OH. The evening includes live music, dancing, a silent auction, wine pull and more.
 
This marks Symon’s second time as Host Chef. A Cleveland native with acclaimed restaurants Lola and Mabel’s BBQ in Cleveland, Roast in Detroit and several locations of B Spot Burgers throughout the Midwest, Symon is renowned in the culinary world. “I am thrilled to participate in this culinary extravaganza in my hometown benefiting University Hospitals Seidman Cancer Center,” said Symon. “It raises vital funds for such an important cause in our community, and I’m honored to have the opportunity to continue to serve as Host Chef of this truly sensational evening.”


Tuesday, January 24, 2017

National Institutes of Health honors research leaders from University Hospitals and Case Western Reserve University with prestigious Outstanding Investigator Awards

CLEVELAND – Two internationally recognized medical research leaders from University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine have received Outstanding Investigator Awards from the National Institutes of Health (NIH). The 7-year, $6.7 million dollar awards, which are the highest honor and largest individual support grants conferred by the NIH, will advance promising molecular studies of colon cancer and age-related cardiovascular risks, respectively. The honored physicians are:
 
Sanford Markowitz, MD, PhD, head of the GI Cancer Genetics Program at the Case Comprehensive Cancer Center, Markowitz-Ingalls Professor of Cancer Genetics at Case Western Reserve University School of Medicine and medical oncologist at UH Seidman Cancer Center, received a National Cancer Institute (NCI) Outstanding Investigator Award.  


Mukesh K. Jain, MD, Chief Scientific Officer, University Hospitals and Harrington Discovery Institute; Chief Research Officer, UH Harrington Heart & Vascular Institute; Vice Dean for Medical Sciences and Professor of Medicine, Case Western Reserve University School of Medicine, received a National Heart, Lung, and Blood Institute (NHLBI) Outstanding Investigator Award. 


Friday, January 13, 2017

UH Seidman Cancer Center receives recognition for cancer care from largest oncology society in United States

CLEVELAND – University Hospitals Seidman Cancer Center has been recognized by the QOPI Certification Program (QCP™), an affiliate of the American Society of Clinical Oncology (ASCO), as successfully completing a three-year certification program for outpatient hematology-oncology practices that meet nationally recognized standards for quality cancer care. QCP builds on ASCO’s Quality Oncology Practice Initiative (QOPI®).
 
In applying for Certification, UH Seidman Cancer Center participated in a voluntary comprehensive site assessment against clearly specified standards that are consistent with national guidelines and was successful in meeting the standards and objectives of QCP.
 
“ASCO’s QOPI certification recognizes those oncology practices that are committed to delivering the highest quality of cancer care,” said ASCO President Daniel F. Hayes, MD, FASCO. “By achieving certification, these practices have demonstrated their commitment to quality and safety excellence in the care they deliver to patients, as well as to the continuous process of quality improvement.”


Monday, January 09, 2017

Has the Affordable Care Act Reduced Socioeconomic Disparities in Cancer Screening?

Out-of-pocket expenditures are thought to be a significant barrier to receiving cancer preventive services, especially for individuals of lower socioeconomic status. A new study looks at how the Affordable Care Act (ACA), which eliminated such out-of-pocket expenditures, has affected the use of mammography and colonoscopy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that use of mammography, but not colonoscopy, increased after the ACA.
 
To determine changes in the use of mammography and colonoscopy among fee-for-service Medicare beneficiaries before and after the ACA’s implementation, Gregory Cooper, MD, of University Hospitals Cleveland Medical Center and the Case Comprehensive Cancer Center, and his colleagues examined Medicare claims data, identifying women ≥70 years old without mammography in the previous two years and men and women ≥70 years old at increased risk for colorectal cancer without colonoscopy in the past five years. The team also identified which patients were screened in the two-year period prior to the ACA’s implementation (2009-2010) and after its implementation (2011-September 2012). 


Friday, December 09, 2016

UH Seidman Cancer Center expert to present novel Triple-Negative Breast Cancer immunotherapy trial at 2016 San Antonio Breast Cancer Symposium

CLEVELAND – A researcher from University Hospitals Seidman Cancer Center will discuss his upcoming immunotherapy clinical trial for triple-negative breast cancer at the 2016 San Antonio Breast Cancer Symposium. The annual symposium is the premier meeting for more than 7,500 physicians and scientists dedicated to breast cancer treatment, featuring state-of-the-art breast cancer research such as experimental biology, etiology, prevention, diagnosis, and therapy of both breast cancer and premalignant breast disease.  
 
Joseph Baar, MD, PhD, Director of Breast Cancer Research at UH Seidman Cancer Center and Associate Professor at Case Western Reserve University School of Medicine, will share details about a phase II clinical trial testing the effectiveness of combining the chemotherapy drugs carboplatin and nab-paclitaxel with an immunotherapeutic agent called pembrolizumab (Keytruda) for use in patients with metastatic triple-negative breast cancer. Dr. Baar’s poster presentation will be part of the Ongoing Trials-Targeted Therapy session on December 8, 2016 from 5 pm to 7 pm.
 
“Up until now, women with triple-negative breast cancer have only had one treatment option, which is chemotherapy. However, more recently, we’ve seen that the immune modulator pembrolizumab improves outcomes in patients with metastatic triple-negative breast cancer,” said Dr. Baar. “As a result, it is now critical to explore how the addition of pembrolizumab to chemotherapy might improve  survival in patients with this type of breast cancer.”



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.